Loading stock data…
U.S. Physical Therapy (USPH)
$68.64-0.14 (-0.20%)
Market OpenUpdated 2:54 PM EDT
U.S.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
U.S. Physical Therapy, Inc. in the Healthcare sector is trading at $68.64 with a market capitalization of $1.0B. Wall Street consensus targets $93.67 (6 analysts), implying a +36.5% move over the next 12 months. The stock is currently 27% below its 52-week high of $93.50, remaining 10.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +36.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $198.29M↓ | $202.73M↑ | $197.13M↓ | $197.34M↑ | $183.79M |
| Gross Profit | $32.75M↓ | $40.13M↑ | $36.87M↓ | $41.62M↑ | $31.07M |
| Operating Income | $14.48M↓ | $22.01M↑ | $19.46M↓ | $24.15M↑ | $14.82M |
| Net Income | -$4.33M↑ | -$10.55M↓ | $5.22M↓ | $7.59M↓ | $12.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.98%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.44%
Volume
Today's trading volume
135,391
Recent News
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
1 Cash-Producing Stock Worth Investigating and 2 We Turn Down
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
How The Story Is Shifting For U.S. Physical Therapy (USPH) As Price Targets Reset
U.S. Physical Therapy’s fair value estimate has been reset from about US$106.83 to roughly US$93.67, marking a clear step down in the implied price target range. Analysts tying this move to recent commentary are balancing optimism around hospital alliances and Medicare rate support with more cautious views on profitability, leverage, and how quickly partnerships can translate into sustained margin gains. As you read on, you will see how this evolving narrative might shape your view of the...
3 Reasons USPH is Risky and 1 Stock to Buy Instead
U.S. Physical Therapy currently trades at $65.04 per share and has shown little upside over the past six months, posting a small loss of 4.3%. The stock also fell short of the S&P 500’s 11.6% gain during that period.
Do These 3 Checks Before Buying U.S. Physical Therapy, Inc. (NYSE:USPH) For Its Upcoming Dividend
Readers hoping to buy U.S. Physical Therapy, Inc. ( NYSE:USPH ) for its dividend will need to make their move shortly...